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ABSTRACT 
Psoriasis is a chronic inflammatory disease with a prevalence in Sweden of 2-3%. 
Stress worsens psoriasis. Serotonin, a monoamine and a neurotransmitter, is a well-
documented signal substance in situations like stress and in regulation of inflammatory 
processes. Serotonin produces its effects via about 21 receptors (R), of which the most 
characterized are 5-HT1AR and 5-HT2AR. The amplitude and duration of activation of 
the serotonergic system is determined by the serotonin transporter protein (SERT). 
 
The aim of the thesis is to elucidate the serotonergic mechanisms involved in psoriasis. 
 
In the first study there was a decreased expression of 5-HT1AR and an increased 5-
HT2AR expression in the involved skin as compared to normal skin. This differential 
expression concord with their antagonistic effects, 5-HT1AR inhibiting inflammation 
and 5-HT2AR promoting inflammation. These two receptors could be potential targets 
for anti-inflammatory therapies in psoriasis. The expression of 5-HT3R was absent in 
involved skin and evident in the basal epidermis of the non-involved skin. 
 
In Study II the expression of SERT was increased in involved skin as compared to non-
involved and normal skin and there was co-localization with caspase-3, a key regulator 
of apoptosis. This indicates that SERT might play a role in regulating apoptosis in 
inflammatory cells in psoriasis. SERT might thus constitute a valuable therapeutic 
target.  
 
In Study III an increased SERT expression in inflammatory cells in the epidermis was 
positively correlated to psoriasis severity and to chronic stress. This implicates that 
SERT expression could be of importance for psoriasis severity and chronic stress. 
 
In the last study, a broad population-based cohort study, SSRI use among patients with 
plaque psoriasis was associated with a decreased need for systemic psoriasis treatment. 
SSRI may have a protective effect in psoriasis. 
 
In conclusion, a role for the serotonergic system was implicated for the chronic 
inflammation in psoriasis. 
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1 INTRODUCTION 
 
1.1 PSORIASIS 
 
1.1.1 Epidemiology 
 
Psoriasis is a common chronic inflammatory disease, affecting around 2% of the 
population in Sweden.
1-3
 Psoriasis is equally common in males and females
4
 and the 
disease can appear at any time of life
5
 with a mean age of onset estimated at 33 years, 
with 75% of cases occurring before 46 years of age.
6
 
 
1.1.2 Clinical features 
 
The most common type of the disease is psoriasis vulgaris, accounting for 90% of all 
cases, in which papulosquamous plaques are well delineated from surrounding normal 
skin. The plaques are red or salmon-pink in color, covered by white or silvery scales, 
and may be thick, thin, large or small. They are most active at the edge: rapidly 
progressing lesions may be annular, with normal skin in the centre. Plaques are usually 
distributed symmetrically, and occur most commonly on the extensor aspects of elbows 
and knees, scalp, lumbosacral region and umbilicus. Active inflammatory psoriasis is 
characterized by the Koebner phenomenon, in which new lesions develop at sites of 
trauma or pressure.
7
 
   Other forms of psoriasis, accounting for 10% of all cases, includes guttate psoriasis, 
generalized pustular psoriasis (von Zumbusch psoriasis), palmoplantar pustulosis and 
erythrodermic psoriasis. Guttate psoriasis, an acute form, in which small papules erupt 
on the trunk, is affecting mostly children and adolescents, being self-limiting and 
resolving within 3–4 months of onset. Generalized pustular psoriasis (von Zumbusch 
psoriasis) is another acute form in which small, monomorphic sterile pustules develop 
in painful, inflamed skin. Palmoplantar pustulosis, consisting of yellow-brown, sterile 
pustules on palms and soles, predominantly affects women (9:1 ratio) and is still 
regarded a variant of psoriasis in the textbooks. However, different demographics and 
genetics imply that the condition may therefore be a comorbidity rather than a variant 
of psoriasis. Erythrodermic psoriasis is a life-threatening condition, where the whole 
body surface is affected by psoriasis, which can lead to hypothermia, 
hypoalbuminaemia, and high output cardiac failure.
5
 
 
1.1.3 Pathogenesis 
 
The scales of psoriasis vulgaris are a result of a hyperproliferative epidermis with 
premature maturation of keratinocytes and incomplete cornification with retention of 
nuclei in the stratum corneum (parakeratosis). The epidermis is thickened (acanthosis) 
with elongated rete ridges as a result of an increased mitotic rate of the basal 
keratinocytes as compared to normal skin. The inflammatory infiltrate mainly consists 
of dendritic cells, macrophages and T cells in the dermis and neutrophils, with some T 
cells in the epidermis. The redness of the lesions is due to increased numbers of 
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tortuous capillaries that reach the skin surface through a markedly thinned 
epithelium.
5,7,8
 
 
1.2 NEUROIMMUNE INTERACTION – PSYCHONEUROIMMUNOLOGY 
 
The skin constitutes one of the major targets for the immune system. There is a 
complex bidirectional brain-immune network, providing a biological basis for the 
ancient anecdotal notion that the mind can play a role in health and disease by its ability 
to influence relevant biological processes.
9
 This brain-immune network, the so-called 
‘brain-skin-axis’ can be activated by stress among other stimuli.  
 
 
Figure 1. The bi-directional brain-immune network – ‘The brain-skin-axis’.9 
 
Stress can activate three independent pathways that are linked with the immune system. 
The first pathway is the hypothalamic pituitary adrenal axis (HPA-axis), where a 
stressful stimulus releases corticotrophin-releasing hormone (CRH) from the 
hypothalamus. CRH then increases the production of adrenocorticotrophic hormone 
(ACTH) from the pituitary. ACTH is in turn released into the circulation and 
transported to the adrenal gland where it stimulates the release of glucocorticoids and 
the stress hormone cortisol from the adrenal cortex. Cortisol then acts as a negative 
feedback loop inhibiting the release of CRH from the hypothalamus.
10
 In chronic 
inflammation this negative feedback loop can be disturbed due to low levels of cortisol 
in serum, leading to a continuous activation of the HPA-axis. 
   The second pathway is the activation of sensory nerves in the brain and skin resulting 
in release of neuroendocrine and neural mediators such as CRH, neurotrophins and α-
melanocyte stimulating hormone, and different neuropeptides active in the skin – 
substance P (SP) and calcitonin gene-related peptide (CGRP). 
  The third pathway is the activation of the autonomic nervous system (ANS). 
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1.3 NEUROIMMUNE INTERACTION IN PSORIASIS 
 
There is an association between the nervous system and psoriasis. In 1971 Dewing
11
 
accidently sectioned a spinal nerve and the psoriasis in the corresponding nerve area 
declined. In retrospective studies there was a correlation between stress experience or 
stressful life events and the onset of guttate psoriasis or the severity of symptoms in 
psoriasis vulgaris. Some studies even demonstrated that stress-experience associates 
with stress axis modulation in psoriasis patients.
12-14
 In prospective studies chronic 
stress worsens psoriasis.
15,16
 Exactly which mediators are involved in the crosstalk 
between the psoriatic skin and the central nervous system (CNS) are not known. There 
are several neurotransmitters that can be involved. 
   Nerve growth factor (NGF), a neurotrophic factor, which is expressed both in the 
nervous system and in the peripheral organs, influences an inflammatory reaction by 
regulating neuropeptides, angiogenesis, cell trafficking molecules and T cell activation. 
NGF augments tissue innervation and plays a critical role in regulating certain 
neuropeptides such as SP and CGRP. Keratinocytes in involved and non-involved 
psoriatic tissue express high levels of NGF compared to controls, and there is a marked 
up-regulation of nerve growth factor-receptor (NGFR) in the terminal cutaneous nerves 
of psoriatic lesions.
17
 NGF is also a mediator of stress responses.
18,19
 
   In the involved skin of psoriasis patients there are more nerve fibers containing the 
sensory neuropeptide SP. These nerve fibers also maintain increasing numbers of 
contacts to Neurokinin 1 receptors (NK1R)-positive mast cells, a target for SP.
20,21
 
Release of SP, which then activates mast cells, could lead to an increased TNFα 
release.
22,23
 TNFα is an important mediator maintaining chronic inflammation and a 
target for the biologics used in the treatment of psoriasis. It seems that acute stress 
suppresses TNFα due to the secretion of catecholamines and glucocorticoids while 
chronic stress increases TNFα, possibly due to the secretion of neuropeptides. 
   One important mediator of stress-induced responses is the neurotransmitter serotonin. 
 
1.4 SEROTONIN 
 
Serotonin (5-hydroxytryptamine; 5-HT), a monoamine, is one of the oldest signalling 
substances to appear during evolution. It was first discovered by Rapport et al. in 1948 
as a potent vasotonic factor and was therefore given the name “tonin”.24,25 Serotonin 
has an important role in normal physiology, including appetite, thermoregulation, sleep 
and pain perception.
26
 Moreover, stress and stress-related hormones increase serotonin 
synthesis.
27,28
 At the cellular level serotonin has effects on proliferation, migration and 
apoptosis.
29
 Like other neurotransmitters such as acetylcholine, glutamate and gamma-
amino butyric acid (GABA), serotonin acts via two categories of receptors: ionotropic 
and metabotropic, where the ionotropic receptors have a low affinity for their 
neurotransmitter ligand but a rapid activation constant, and the metabotropic receptors 
(G-protein activated) exhibit both a high affinity for their neurotransmitter and a slow 
activation constant.
26
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1.4.1 Serotonin synthesis 
Serotonin is synthesized via enzymatic cleavage from its precursor tryptophan by a rate 
limiting enzyme, tryptophan hydroxylase (TPH).
30
 Hydroxytryptophan is then further 
decarboxylated to serotonin by L-aromatic amino-acid decarboxylase with the cofactor 
pyridoxal phosphate.  
   Tryptophan is an essential amino acid in humans obtained from dietary sources. 
Tryptophan is very effective in capturing light, and it is formed in the reactive core of 
chlorophyll in plants.
31
 Serotonin is involved in root growth and helps out as a potent 
antioxidant in cell metabolism and leaf motility in plants. In humans TPH is found in 
brainstem neurons, pineal glands, lungs, gut and also skin, where it has been localised 
to blood vessels, mast cells, melanocytes, keratinocytes and fibroblasts.
32
 
 
1.4.2 Serotonin degradation  
Degradation of serotonin mainly occurs through oxidative deamination in the liver and 
in lung endothelial cells, where serotonin is stored in vesicles until being released and 
catalysed by monoaminoxidase (MAO) which is expressed in mammalian skin.
33
 MAO 
deaminates serotonin to 5-hydroxyindole acetaldehyde, which is followed by its 
transformation to 5-hydroxyindole acetic acid (5-HIAA). 5-HIAA is excreted in the 
urine and serves as an indicator of serotonin transmission in the body. 
   Stress induces activation of the HPA-axis resulting in increased levels of 
glucocorticoids, which stimulate serotonin turnover and synthesis. It has been shown 
that treatment with dexamethasone, a synthetic adrenal steroid, increases TPH protein 
concentration in brainstem neurons.
27
 In the periphery, 5-HIAA and serotonin turnover 
is increased in patients showing an elevated cortisol level.
34
 
 
1.4.3 Localisation 
Serotonin occurs at the highest concentrations in three locations in the body:  
1. In the wall of the intestine. About 90% of the total amount of serotonin in the 
body is present in enterochromaffin cells, which are mainly located in the 
stomach and small intestine. 
2. In blood. Serotonin is present in high concentration in platelets, which 
accumulate it from the plasma by an active transport system and release it when 
they aggregate at sites of tissue damage. 
3. In the CNS, acting as a neurotransmitter.35 
 
1.4.4 Role of serotonin in skin inflammation 
In the inflammatory skin serotonin expression is limited to platelets.
36,StudyII
 In chronic 
eczema and psoriasis serotonin expression has been evident in the cytoplasm of prickle 
cells, sweat gland cells, sebaceous gland cells, and hair roots, while no expression was 
evident in normal skin.
37,38
 A recent report determined that there was an expression of 
serotonin in mast cells in urticaria pigmentosa.
39
 In earlier studies serotonin was also 
expressed in melanocytes.
40,41
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1.5 SEROTONIN RECEPTORS 
 
The actions of serotonin are mediated through interaction with membrane-bound 
receptors which are categorized into 7 families (5-HT1 – 5-HT7) with at least 21 
subtypes.
26
 Most of these are, as described above, metabotropic receptors coupled to G 
proteins, except the 5-HT3 receptor family which are ionotropic receptors.  
   The human skin expresses these membrane-bound receptors. Detailed molecular 
analyses have identified mRNA encoding for 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-
HT2C and 5-HT7 receptors.
42
 In situ studies have also demonstrated expression of the 
5-HT3R in the basal epidermal layer in the skin,
43,StudyI
 while pharmacological studies 
indicate that 5-HT3R are expressed on sensory nerve endings.
44
 
 
The best-characterized receptor is 5-HT1AR, which is a high-affinity receptor. It is 
stimulated by normal circulating levels of day-time serotonin and mediates promotion 
of mitogen-activated T and B cell survival, associated with increased translocation of 
the transcription factor Nucleus factor kappa beta (NFκβ) to the nucleus.45 Activation 
of 5-HT1AR can also induce the release of S100beta from astrocytes.
46
 It has been 
reported that 5-HT1AR is important in preventing apoptosis in neuronal cells and 
hippocampal HN2-5 cells.
47
 Conversely it may be pro-apoptopic through c-Jun N-
terminal kinase in Chinese hamster ovary fibroblasts.
48
 Hence activation of the 5-
HT1AR leads to neurite outgrowth
49
 and maybe neuronal survival as well.
50
  
   The 5-HT2AR is a low-affinity receptor and only activated when serotonin levels are 
high. Activation of 5-HT2AR is associated with an increase in kinase activity and with 
cell division and apoptosis through increasing phosphatidylinositol-hydrolysis, which 
leads to increased intracellular Ca
2+
 levels. Thus 5-HT2AR increases cell 
proliferation.
29
 In rats, cutaneous expression of 5-HT2AR was detected in 
unmyelinated axons at the dermal – epidermal junctions and in the nerve endings of 
Pacinian corpuscles.
51
 In eczematous skin of mice there was 5-HT2AR 
immunoreactivity in the epidermis and on nerve endings.
52
 
   The 5-HT7R has been suggested to have a role in pain and migraine, via actions on 
blood vessels, but also on neurogenic inflammation.
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1.5.1 Role of serotonin receptors in skin inflammation 
 
1.5.1.1 5-HT1A receptor 
Serotonin promotes inflammation by increasing the number of mast cells at the site of 
tissue injury, via the 5-HT1AR.
53
 Expression of 5-HT1AR in inflamed skin is 
associated with melanocytes, keratinocytes in the upper part of the epidermis, mast 
cells and in vessel walls. In the same study of human contact allergy skin there was a 
decrease in the number of 5-HT1AR positive cells in the eczematous skin compared to 
normal skin.
36
 
   Buspirone, a non-selective 5-HT1AR agonist, applied topically or orally, was able to 
diminish contact allergy in mice.
54
 Tandosporine, another agonist, has been reported to 
decrease stress and to attenuate itching in patients with atopic dermatitis.
55,56
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1.5.1.2 5-HT2A receptor 
In humans Study I revealed expression of 5-HT2AR in mononuclear cells in the 
papillary dermis of psoriatic skin. These were CD3 positive, indicating these cells to be 
lymphocytes. These cells are increased in involved compared to non-involved psoriatic 
skin and normal healthy skin, as well as increased in allergic contact dermatitis skin 
compared to control skin.
36
  
   Different 5-HT2AR antagonists have been reported to be able to decrease contact 
allergic reactions in mice.
57,58
 Of such antagonists, ketanserin inhibits the established 
but not challenge-induced phase of allergic contact dermatitis to nickel in humans.
59,60
 
   In aortic smooth muscle cells activation of 5-HT2AR, with the agonist - 2,5-
dimethoxy-4-iodoamphetamine (DOI) provides an inhibition of TNFα-mediated 
inflammation.
61
 
 
1.5.1.3 5-HT3 receptor 
When injected intradermally serotonin gives rise to pruritus in humans.
44
 This may be 
mediated through different receptors such as the 5-HT3 receptor. Thus ondansetron, a 
5-HT3 antagonist, is able to decrease pruritus. In addition, pruritus in malignant disease 
has been treated with paroxetine, a selective SSRI, and the antipruritic action was 
connected with a down-regulation of 5-HT3 receptors.
62
 
 
 
 
1.6 SEROTONIN TRANSPORTER PROTEIN 
 
Serotonin in the plasma can be transferred to platelets by the serotonin transporter 
protein (SERT), which is a 12-membrane spanning molecule that regulates both the 
release and uptake of serotonin. The release of serotonin from platelets is mediated by 
SERT. SERT moves serotonin into the cells in most situations and there are a large 
number of pharmaceutical drugs that can inhibit this reuptake process, namely 
serotonin reuptake inhibitors (SSRI) that are used in the treatment of depression. 
   Some individuals are prone to be more sensitive than others to stress and depression 
due to polymorphisms in the promoter or intron region of the SERT gene.
63,64
 In 
psoriasis no significant differences in genotype distribution and allele frequencies were 
apparent in a German population.
65
 
 
1.6.1 Role of serotonin transporter protein in inflammation 
 
No earlier studies have focused on SERT expression in the skin. Platelet SERT appears 
to be identical to that carried by neurons and stored serotonin can be rapidly released in 
response to a variety of inflammatory signals.
66
 Lymphocytes also carry SERT. The 
high affinity uptake of serotonin by peripheral blood lymphocytes has been described 
with corresponding inhibition by SSRI.
67
 
  The results of studies of intestinal inflammation in experimental animals and humans 
regarding mucosal expression of SERT have been inconsistent. For instance, the levels 
of SERT mRNA have been reported to be elevated in the small intestines of patients 
with irritable bowel syndrome (IBS),
68
 reduced in rectal biopsies of patients with 
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ulcerative colitis and IBS,
69
 and in guinea pig colitis
70
 and normal in rectal and 
sigmoidal mucosal biopsies of patients with IBS.
71
  
   Other important cytokines in chronic skin inflammation might be affected by SERT. 
In cultured colonic epithelial cells SERT function and expression decreases IFNγ and 
TNFα.72 It has been reported that SERT synthesis may be stimulated by another 
cytokine important for psoriasis pathogenesis, IFNα.73 
 
 
1.7 SEROTONIN REUPTAKE INHIBITORS 
 
Serotonin reuptake inhibitors (SSRI) are a family of antidepressants with more-or-less 
the same mode of action. The most common SSRI in Sweden are: citalopram, 
escitalopram, paroxetine, fluoxetine, fluvoxamine and sertraline. 
   The mechanism of action of SSRI is simply explained by selective inhibition of 
SERT. SSRI immediately blocks the serotonin reuptake pump, and this action causes a 
sudden increase in serotonin, predominantly in the somatodendritic area as compared to 
the axon terminals where serotonin is presumably needed in order to exert its 
therapeutic actions. This might explain why SSRI do not have a rapid onset of 
therapeutic effect. In the longer term, this sustained increase of serotonin causes the 
somatodendritic 5-HT1A autoreceptors to desensitize and the neuronal impulse flow is 
turned on, which means that more serotonin releases from the axon terminal. The final 
step of action is the desensitization of post-synaptic serotonin receptors, leading to 
serotonin release in the axon terminal.
74
 
   There might be other pathways of action for SSRI in the treatment of depression such 
as neuroplasticity. Treatment with escitalopram in the rat frontal cortex activated 
intracellular pathways linked to brain-derived neurotrophic factor (BDNF) and 
increased the levels of Pro-brain-derived neurotrophic factor, hence contributing to 
synaptic plasticity.
75
 
 
1.7.1 Role of serotonin reuptake inhibitors in skin inflammation 
 
Treatment with SSRI can lead to cutaneous side-effects such as spontaneous bruising, 
pruritus, urticaria, angioedema, erythema multiforme, Stevens-Johnson syndrome, toxic 
epidermal necrolysis, erythema nodosum, alopecia, hypertrichosis and leukocytoclastic 
vasculitis.
76
 Interestingly, case reports on the effect of SSRI in psoriasis have yielded 
conflicting results; one study indicated improvement of psoriasis after use of 
paroxetine
77
 and three studies indicated a flare-up or worsening of the psoriasis 
following fluoxetine and paroxetine treatments.
78-80
 
 Patients with depression have elevated blood levels of cytokines as compared to 
healthy controls, and these levels are reduced upon treatment with SSRI.
81,82
 In patients 
who failed to respond to SSRIs, no reduction in cytokine levels was observed,
83
 
suggesting a connection between SSRI, depression and the immune system.  
   In humans and in an animal arthritis model there was a suppressed inflammatory 
cytokine production through treatment of fluoxetine and citalopram, i.e. anti-
inflammatory effects.
84
 In rats fluoxetine has also suppressed inflammatory responses 
in lung tissue and inhibited the expression of inflammatory cytokines, interleukin-1β, 
TNFα, monocyte chemotactic protein and intercellular adhesion molecule-1.85 There is 
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further evidence for an anti-inflammatory effect of SSRI. In a rat model of periodontitis 
fluoxetine suppressed the inflammatory response and protected against periodontal 
bone resorption and destruction of collagen fibers.
86
 In a murine colitis model 
fluoxetine inhibits NFκB activation in intestinal epithelial cells and hence ameliorates 
acute murine colitis.
87
 In animal models of septic shock and allergic asthma, fluoxetine 
reduced the inflammatory reaction.
88
 
   There are no earlier studies of SSRI and skin inflammation. 
 
1.8 SWEDISH HEALTHCARE REGISTERS 
 
Sweden has a long tradition of healthcare registers. Already in 1749 there was a 
nationwide cause-of-death register introduced.
89
 The structure of the Swedish 
healthcare system, reliable healthcare registers and the unique personal identification 
number (PIN)
90
 offers exceptional possibilities for performing register-based 
epidemiological studies in Sweden. 
 
1.8.1 National Patient Register 
 
In 1964 the National Board of Health and Welfare launched the National Patient 
Register (NPR). Since 1987 the register has a nearly complete coverage of all inpatient 
care (both public and private). From 2001 data from specialized out-patient care is 
included (both public and private) with primary care being excluded.
91
 It is estimated 
that the outpatient register has 80% coverage
92
 due to lower reporting from private 
caregivers and low reporting data in psychiatric care. Private care is estimated to 
sustain less than 10% of all healthcare in Sweden. Regarding accuracy, a validation 
from the Swedish National Board of Health and Welfare in 2007 reported that more 
than 98% of all diagnoses had been technically correctly coded with only 1-2% 
dropouts and 1% missing data. 
91
 Other studies with validations of medical records of 
the inpatient care registered in NPR have shown varying positive predictive values 
between 85-94%.
92,93
 No validation of the specific diagnosis of psoriasis vulgaris has 
been performed. 
   Since 1997 diagnoses in the register are coded according to the International 
Classification of Diseases, 10
th
 revision (ICD-10). Register information includes patient 
characteristics (PIN, sex, age, and county of domicile), administrative data, hospital 
identification and medical data (major interventions and discharge diagnoses, with one 
main diagnosis and up to seven secondary discharge diagnoses and dates of diagnosis). 
 
1.8.2 Prescribed Drug Register 
 
In 1999 the Prescribed Drug Register (PDR) was started and since 1
st
 July 2005 the PIN 
was included. The register offers complete coverage of all dispensed drugs in Sweden, 
where each dispensation is connected to an individual. It is updated every month and 
contains approximately 90 million prescriptions annually. Only dispensed drugs are 
captured since the register is pharmacy-based.
94
 All pharmacies in Sweden report to the 
register. Pharmacy dispensing is considered as the golden standard in drug exposure 
information.
95
 
   9 
   The register measurements units are PIN, type of drug described, date of prescription 
and dispensing and Defined Daily Doses (DDDs). All drugs are classified according to 
the Anatomical Therapeutic Chemical (ATC) classification system. The DDD is the 
assumed average maintenance dose per day for a drug used for its main indication in 
adults.
96
 The database is complete for the entire population in the country (patient 
identity data are missing for <0.3% of all items).
94
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2 AIMS OF THE STUDIES 
 
2.1 OVERALL AIM  
 
To study the serotonergic mechanisms in psoriasis and its impact on disease. 
 
2.2 SPECIFIC AIMS 
 
 Study the expression of serotonergic receptors (5-HT1AR, 5-HT2AR, and 5-
HT3R) in involved and non-involved psoriatic skin as compared to normal skin 
and characterization of cells and structures expressing these receptors (Study I). 
 
 Study the expression of SERT and serotonin in involved and non-involved 
psoriatic skin as compared to normal skin, characterization of cells and 
structures expressing SERT and serotonin and their relation to apoptosis (Study 
II). 
 
 Study if the altered SERT expression determined in Study II correlates to 
psoriasis severity, depression, and chronic stress (Study III). 
 
 Study if modulation by the serotonergic system can improve or worsen psoriasis 
by studying SSRI and its effect in psoriasis (Study IV). 
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3 PATIENTS AND METHODS 
 
STUDIES  I – III 
 
3.1 SUBJECTS 
 
Patients were recruited from the Department of Dermatology, Karolinska University 
Hospital with stable plaque psoriasis, without ongoing systemic treatment who had not 
received topical treatment (except emollients) for at least two weeks. Control patients 
were recruited from the same area and were healthy regarding inflammatory 
dermatoses (Studies I-II). 
 
In Study III patients were recruited from the Department of Dermatology, Karolinska 
University Hospital and from treatment units at the Psoriasis Association in Stockholm 
with the same criteria as described above. 
 
3.2 CLINICAL MEASUREMENTS (STUDY III) 
 
3.2.1 Psoriasis Area and Severity Index 
The clinical severity of psoriasis in each patient was assessed using the Psoriasis Area 
and Severity Index (PASI).
97
 
  
3.2.2 Salivary cortisol test 
Nineteen of the 20 patients with psoriasis took part in the salivary cortisol test. Salivary 
cortisol samples were collected in plastic vials at 08.00h for four consecutive days. At 
22.00h on the third day each patient was asked to take 0.25 mg dexamethasone orally, 
which was followed by a cortisol test the following morning. These samples were 
stored at -20°C until analysed. The cortisol concentration was determined using a 
radioimmunoassay kit (Spectria Cortisol; Orion Diagnostica, Espoo, Finland). A 
salivary cortisol quotient was determined by dividing the mean of the three initial 
cortisol values by the last cortisol value following the dexamethasone challenge. A low 
ratio is an indicator of chronic stress.
98,99
  
 
3.2.3 Beck’s Depression Inventory 
Symptoms of depression of each patient with psoriasis were assessed using Beck’s 
Depression Inventory (BDI), which consists of 21 questions. A score of 21 or more 
represents depression.
100
 
 
 
3.3 IMMUNOHISTOCHEMISTRY  
 
Punch biopsies of 3 mm diameter were obtained from the edge of the involved and non-
involved skin (at least 5 cm away from the plaque) on the lower back of patients. 
Biopsies were taken from the same site from the healthy controls.  
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   The skin specimens were first immersed in phosphate-buffered 4% formaldehyde 
containing 0.17% picric acid for 2 h and thereafter rinsed in 0.1 M Sörensen’s 
phosphate-buffered saline (PBS) supplemented with 10% sucrose for at least 24 h. The 
samples were then frozen rapidly on dry ice and stored at -70
o 
C until further 
processing. While still frozen the biopsy material was embedded in Tissue Tek OCT 
Compound (Sakuro Finetek, Zoeterwoude, Netherlands), cut to 14-µm thick sections 
with a Microm HM500 cryostat (Heidelberg, Germany), and mounted on 
SuperFrost/Plus glass slides (six sections on each slide) for immunohistochemical 
staining. 
 
3.3.1 Biotinylated streptavidine method 
 
After blocking of non-specific binding sites with normal serum, sections were 
incubated with the primary antibodies overnight at 4°C. The following day sections 
were incubated with a biotinylated secondary antibody (Vector Laboratories, 
Burlingame, CA, USA) for 40 min at room temperature. Finally, a fluorochrome was 
added to visualize the primary antibody. Fluorochromes used were a Cy2-labelled 
streptavidine (Amersham Pharmacia Biotech, Uppsala, Sweden) with a green 
fluorescence (Study III) and streptavidine-conjugated Texas Red (Vector Laboratories) 
with a red fluorescence (Studies I-III).  
 
 
Table 1. Primary antibodies for immunohistochemical staining 
 
Antibody Type Company Dilution 
Used 
in 
study 
Fluorochrome 
5-HT 
Poly 
(rabbit) 
Diasorin, Millwater, 
USA 
1:10000 II Cy2 
SERT 
Mono 
(mouse) 
MabTechnologies, 
Stone Mountain, 
USA 
1:2500 – 
1:10000 
II, III 
Cy 2, 
Texas Red 
5-HT1AR 
Poly 
(rabbit) 
Azmitia et al.101 1:1000 I Texas Red 
5-HT2AR 
Mono 
(mouse) 
Pharmingen, San 
Diego, USA 
1:150 I Texas Red 
5-HT3R 
Poly 
(rabbit) 
Morales et al.102 1:4000 I Texas Red 
 
For 5-HT and 5-HT1AR antibodies preadsorption with each antigen eliminated the 
immunostaining. For the 5-HT3R antibody a preimmune serum was used as control. 
For the monoclonal antibodies (SERT and 5-HT2AR) control staining with non-
specific mouse IgG of the same isotype (Dako, Glostrup, Denmark) and in the same 
dilution as the primary antibodies were negative. Additionally, for each observation and 
every patient, the primary antibody was omitted in two sections and no staining was 
observed.  
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3.3.1.1 Double staining 
 
The sections were treated as described above and then subjected to a second blocking 
of non-specific binding sites. Next, another primary antibody was added and the 
sections were incubated overnight at 4°C. The following day sections were incubated 
with secondary antibodies that were associated with a fluorochrome, either FITC-
conjugated (green label) or Alexa Fluor-conjugated (green label). As a control the 
primary antibody was omitted in two sections and no staining was recorded. In two 
sections the second primary antibody was being stained in the absence of the first 
primary antibody. 
 
Table 2. Antibodies for double staining procedures. 
 
Antibody Type Company Dilution 
Stained 
With 
Used 
in 
study 
Fluorochrome 
Caspase-3 
Poly 
(rabbit) 
R&D Systems, 
Minneapolis, USA 
1:100 SERT II 
FITC-conjugated 
swine-antirabbit 
CD1a 
Mono 
(mouse) 
Becton-Dickinson, 
Franklin Lakes, 
USA 
1:100(I) 
,1:320 
(II) 
5-HT1A 
(I), SERT 
(II) 
I,II 
Texas Red (I), FITC-
conjugated donkey 
anti-mouse (II) 
CD1a 
Mono 
(mouse) 
BD Pharmingen, 
Franklin Lakes, 
USA 
1:20 (I), 
1:25 
(III) 
5-HT2A 
(I), SERT 
(III) 
III 
FITC-conjugated 
donkey anti-
mouse(I)  
Alexa Fluor-
conjugated donkey 
anti-mouse (III) 
CD3 
Mono 
(mouse) 
Becton-Dickinson 1:100 5-HT1A I Texas Red 
CD3 
Poly 
(rabbit) 
Novocastra Lab, 
Newcastle, UK 
1:50 SERT II 
FITC-conjugated 
swine-antirabbit 
CD4 
Mono 
(mouse) 
Becton-Dickinson 1:40 5-HT1A I Texas Red 
CD8 
Mono 
(mouse) 
Becton-Dickinson 1:40 5-HT1A I Texas Red 
LAMP 
Mono 
(mouse) 
Immunotech SAS, 
Marseille, France 
1:25 SERT III 
Alexa Fluor-
conjugated donkey 
anti-mouse 
NK1-
beteb 
Mono 
(mouse) 
Sanbio BY, Am 
Uden, Netherlands 
 
1:80 5-HT1A I Texas Red 
Tryptase 
Mono 
(mouse) 
Chemicon, 
Temecula, USA 
1:5000 5-HT1A I Texas Red 
Tryptase 
Poly 
(rabbit) 
Gift from 
Harvima103 
1:1000 SERT II 
FITC-conjugated 
swine-antirabbit 
 
 14 
3.3.2 Microscopy 
 
Sections were mounted with glycerol⁄gelatin (Merck, Darmstadt, Germany), covered 
with glass coverslips and then examined using a fluorescence Zeiss Axioskop 2 MOT 
microscope (Carl Zeiss, Stockholm, Sweden) in Studies II and III.  
   In Study I the sections were mounted with glycerol/PBS and then covered with glass 
coverslips. For microscopic evaluation a Nikon Microphot-FXA microscope was used 
(Nikon Corporation, Yokohama, Japan). 
 
The numbers of labelled cells in involved, non-involved and normal skin respectively, 
were counted by the same observer. For each patient the numbers of cells were counted 
in a blinded way in four different sections. The average values were used to calculate 
the mean ± SD value for all of the specimens. In Study I the 5-HT1A and 5-HT2A cells 
were counted in the papillary dermis. In Studies II and III the SERT-positive cells were 
counted separately for the epidermis and papillary dermis.  
 
3.3.2.1 Double staining 
In Study I the 5-HT1A and 5-HT2A positive cells in the papillary dermis were counted 
in two sections per sample and then the double stained cells with each antibody 
(tryptase, CD1a, CD3, CD4, CD8, and NK1-beteb) were counted and expressed as 
“majority of 5-HT1A cells were positive for…”. 
   In Study II 7/10 biopsies were double stained and two sections per patient were 
counted and expressed as mean percentages. In this case each positive, double-stained 
cell with antibody (CD1a, CD3 and tryptase) was counted and then the expression of 
SERT was counted and expressed as a percentage of CD1a-, CD3-, and tryptase 
positivity, respectively. For caspase-3 the SERT-positive cells were counted and then 
the caspase-3-positive cells were counted and expressed as a percentage of SERT- 
positive cells. 
   In the case of double staining in Study III 7/20 subjects were examined and the 
numbers of epidermal SERT-positive cells were counted in two sections per sample 
and then the epidermal cells double stained for the other primary antibodies (CD1a and 
LAMP) were counted and expressed as a percentage of SERT-positive cells. 
 
 
3.4 STATISTICAL ANALYSIS 
 
To compare the total numbers of labelled cells in involved and non-involved skin 
compared to normal skin the Mann-Whitney U-test was used (Studies I, II) For within-
group analysis to compare between involved and non-involved skin the Wilcoxon 
signed rank test was used (Studies I,II,III).  
    In Study III the Pearson correlation coefficient was used to measure the strength of a 
linear correlation between number of cells expressing SERT in the epidermis and 
papillary dermis, and in PASI and BDI, respectively. The Spearman correlation 
coefficient was used to measure the strength of a linear correlation between number of 
cells expressing SERT in the epidermis and papillary dermis and salivary cortisol ratio 
levels. 
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   A p-value of <0.05 (two-tailed) was considered to be statistically significant. All the 
analyses were carried out using SAS software (SAS Institute, Cary, NC, USA).  
   In Study III missing data was handled by exclusion from correlation for one patient 
regarding salivary cortisol level and for one patient regarding numbers of SERT-
positive cells in the papillary dermis and epidermis. 
 
 
STUDY IV 
 
 
3.5 SUBJECTS 
 
The source population was all Swedish residents ever diagnosed with plaque psoriasis 
by dermatologists (ICD; L40.0, L40.5, L40.8-9) and registered in the National Patient 
Register (in-hospital care 1997-2006 and outpatient care 2001-2006). In total, 69830 
patients were identified.  
 
3.5.1 Exposed cohort 
 
The cohort of SSRI-exposed subjects (n=1282) had a prescription dispensed of 
fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine, or escitalopram twice 
during a period of six months at a Swedish pharmacy between 1
st
 July 2006 and 1
st
 
April 2008. To assure incident SSRI treatment we conformed to a wash-out period of at 
least one year without any dispensed SSRI drugs. Cohort entry was defined as date for 
dispensed SSRI prescription. Psoriasis disease severity was classified according to the 
last psoriasis treatment dispensed (systemic or non-systemic) up to six months prior to 
cohort entry. Severe psoriasis was defined as use of systemic treatment (methotrexate, 
cyclosporine, acitretin, and biologics (etanercept, infliximab, efalizumab and 
infliximab)), while patients without systemic treatment were classified as having mild 
psoriasis. This method for psoriasis classification has previously been used and 
validated in several publications.
104-107
 
 
3.5.2 Reference cohort 
 
The reference cohort included patients from the source population with psoriasis but 
unexposed to SSRI (n=1282). Reference patients were matched for age, sex, county of 
domicile, psoriasis severity (systemic or non-systemic psoriasis treatment), and for 
seasonal variation. Seasonal variation was matched between the two cohorts as same 
date of psoriasis drug disposure ± 2 months. 
 
 
3.5.3 Main outcome measure 
 
The main outcome measure was change in psoriasis severity by means of switching 
psoriasis treatments from systemic to non-systemic or vice versa six months after 
exposure to SSRI. Outcome was measured between six-to-twelve months after cohort 
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entry, defined as first psoriasis drug dispensation or absence of psoriasis drug 
dispensation. 
 
3.6 STATISTICAL ANALYSIS 
 
To measure change in psoriasis severity we studied switching or not switching in 
psoriasis treatments, from systemic to non-systemic treatment and vice versa in our two 
cohorts – exposed and unexposed to SSRI (binary outcome and binary predictor). 
Conditional logistic regression was used to determine the odds ratio (OR) and 95% 
confidence interval (CI) of switching psoriasis treatments after exposure to SSRI. The 
OR was adjusted for age, sex, and county. Age was divided into 10-year strata and 
counties in Sweden divided into three regions, one rural and two urban. We also 
performed a sensitive analysis for DDD of SSRI at three levels: low, medium, and high. 
SAS 9.2 was used for statistical analyses. 
 
 
STUDIES I-IV 
 
 
3.7 ETHICS APPROVAL 
 
All studies in this thesis were approved by a Regional Ethical Review Board. For 
Studies I-III informed consent was obtained from the patients prior to enrolment in the 
studies. For Study IV the Regional Ethical Review Board in Stockholm did not require 
informed consent from the patients. 
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4 RESULTS 
 
4.1 STUDY I 
 
4.1.1 5-HT1A receptor 
 
There was a decreased expression of 5-HT1AR positive cells in the papillary dermis in 
involved (p<0.001) and non-involved skin (p<0.001) compared to normal skin. No 
difference was recorded between the involved and non-involved skin. The majority of 
5-HT1AR-positive cells were tryptase positive, with a few CD4 and CD8 positive cells. 
There was also 5-HT1AR immunoreactivity in the vessel walls.  
   In the normal and non-involved skin there were immunoreactive cells in the basal 
epidermis. Double staining of these cells with NK1-beteb indicated that they were 
melanocytes. There was also 5-HT1AR immunoreactivity of a reticular pattern in the 
upper part of the epidermis, staining 25% of the keratinocytes in the normal and non-
involved skin and up to 40% in the involved skin. 
 
4.1.2 5-HT2A receptor 
 
There was an increased expression of 5-HT2AR-positive cells in papillary dermis in 
involved skin as compared to both normal (p<0.001) and non-involved skin (p<0.01). 
Nearly all 5-HT2AR positive cells were CD3 positive. 
 
4.1.3 5-HT3 receptor 
 
There were 5-HT3R positive cells in the basal part of the epidermis in non-involved 
skin, which were absent in the involved skin. The acrosyringium of involved skin 
exhibited immunoreactivity.  
 
4.2 STUDY II 
 
4.2.1 Serotonin 
 
Serotonin was present in the platelets of the involved skin. There was also a focal 
expression in keratinocytes in 2/10 biopsies of the involved skin. These two biopsies 
had a high grade of inflammation and acanthosis. In the non-involved skin 1/10 
biopsies exhibited diffuse keratinocyte expression. Normal skin had expression of 
serotonin in 1/10 biopsies with a weak staining in the apical part of epidermis. 
 
4.2.2 SERT 
There was an increased expression of SERT-positive inflammatory cells in the 
epidermis in the involved skin as compared to normal skin (p<0.05). There was also an 
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increased expression of SERT-positive mononuclear cells in the papillary dermis in the 
involved skin as compared to both non-involved (p<0.01) and normal skin (p<0.01).  
   In the involved skin 7/10 biopsies had focal or basal epidermal immunoreactivity as 
compared to apical epidermal immunoreactivity in 5/10 biopsies of the non-involved 
skin. In normal skin weaker apical epidermal immunoreactivity was evident in 8/10 
biopsies. Intense SERT immunoreactivity was evident in adnexal structures, 
irrespective of skin inflammation. 
   Double staining revealed that the SERT-positive cells could express CD1a, CD3, and 
tryptase. A majority of the SERT-positive cells in the papillary dermis expressed 
caspase-3. Among the SERT-positive dendritic epidermal cells, only a few stained for 
caspase-3. 
 
4.3 STUDY III 
 
PASI values of the patients varied from 4-45 with a mean value ± standard deviation of 
17±10. The mean of the cortisol ratio levels was 2.9±2.7 and the BDI score was 
10.0±9.4. 
   As in study II the expression of SERT-positive cells in dermis in the involved 
psoriatic skin, with a mean ±SD value of 10.5±7.7 was increased as compared to the 
SERT positive cells in dermis in the non-involved skin, with a mean ±SD value of 
0.9±1.8 (p<0.001). The expression of SERT-positive cells in epidermis in the 
involved psoriatic skin, (Fig. 1a) with a mean ±SD value of 5.0±4.4 was increased as 
compared to the SERT-positive cells in epidermis in the non-involved skin, with a 
mean ±SD value of 1.9±2.4 (p< 0.001). 
 
4.3.1 Correlation data 
 
There was a correlation between PASI and the numbers of SERT-positive 
inflammatory cells in the epidermis of the involved skin (r=0.53; p<0.05). There was 
also a high tendency for a positive correlation between PASI and the numbers of 
SERT-positive cells in the epidermis of the non-involved psoriatic skin (r=0.44; 
p=0.06). Furthermore, a negative correlation between salivary cortisol ratio levels and 
the numbers of SERT-positive cells in the epidermis of the involved skin (r=-0.46, 
p<0.05) was evident. A low level of salivary cortisol ratio indicates chronic stress; our 
finding therefore indicates that an increased epidermal SERT expression in psoriasis 
correlates with chronic stress. 
   No correlation was observed between dermal SERT expression in involved and non-
involved skin and PASI or salivary cortisol ratio levels, respectively. No correlation 
was determined between epidermal and dermal SERT expression in involved and non-
involved skin and BDI. 
 
4.3.2 Double staining 
 
Double staining revealed that 73% of the SERT-positive epidermal cells were positive 
for CD1a and 50% were positive for LAMP. These findings strongly indicate that the 
SERT-positive epidermal cells are dendritic cells (both immature and mature). 
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4.4 STUDY IV 
 
Sixty-four percent of the patients were females. The mean age was 55 years among 
both the exposed and the reference cohort. At cohort entry 89% were classified as 
having mild psoriasis (Table 3).  
 
 
Table 3. Basic characteristics of the two cohorts 
Characteristics Exposed group Reference group 
 n=1282 n=1282 
Sex     
   Female 482 36% 482 36% 
   Male 800 64% 800 64% 
     
Age      
   0-19 28 2% 28 2% 
   20-39 265 21% 265 21% 
   40-59 442 34% 442 34% 
   60-79 421 33% 421 33% 
   80- 126 10% 126 10% 
     
   Median (IQR) 57(41,69)  56(41,68)  
   Mean 55.0  54.6  
     
Psoriasis severity     
   Mild (no systemic treatment) 1136 89% 1136 89% 
   Severe (systemic treatment) 146 11% 146 11% 
     
 
 
Among those with mild psoriasis 29 patients switched from non-systemic to systemic 
treatments after exposure to SSRI as compared to 64 patients in the reference group 
(OR 0.44  95% CI 0.28-0.68) (Table 4). Among study subjects classified with severe 
psoriasis, 42 patients switched from systemic to non-systemic treatment after SSRI use 
as compared to 37 patients in the reference group (OR 1.20 95% CI 0.71-2.02) (Table 
4). Both these findings indicate that SSRI may have a protective effect in psoriasis. 
   To assess whether this effect might be dose-dependent we investigated days covered 
with DDDs of SSRI and changes in psoriasis severity. Among those with more than 
90% of days covered with 1 DDD/day of prescribed SSRI and mild psoriasis, 23 
patients switched treatments after SSRI use as compared to 49 patients in the reference 
group (OR 0.45 95% CI 0.27-0.75). The protective effect of SSRI is also seen among 
those with 40-90% of days covered with 1 DDD/day of prescribed SSRI, where four 
patients with mild psoriasis switched treatments after SSRI use as compared to 13 
patients in the reference group (OR 0.30 95% CI 0.10-0.93) (see Table 4, manuscript 
IV).  
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Table 4. Number of persons switching and risk of switching psoriasis treatments before vs. after SSRI 
exposure. The risks are depicted as adjusted odds ratios with 95% confidence intervals adjusted for 
age, sex, and county. 
Treatment at 
baseline 
Exposed 
cohort 
(No=1282) 
 
Reference 
cohort 
(No=1282) 
 
Adjusted odds 
ratio (95%CI) 
      
Non-systemic      
   No Switch 1107 97.4% 1072 94.4% Reference 
   Switch (NS→S) 29 2.6% 64 5.6% 0.44 (0.28-0.68) 
 Total 1136  1136   
      
Systemic      
   No switch 104 71.2% 109 74.7% Reference 
   Switch (S→NS) 42 28.8% 37 25.3% 1.20 (0.71-2.02) 
Total 146  146   
 
   Finally, we also studied whether this protective effect of SSRI was maintained 
between males and females. When stratified for sex, the odds ratio of switching 
treatments from non-systemic to systemic treatment after SSRI use was 0.51 for males, 
(95% CI 0.28-0.96) and 0.37 for females, (95% CI 0.19-0.71) (data not included). 
   We determined no major difference between the exposed and reference cohort in the 
use of phototherapy and the geographical distribution of the patients (data not 
included). 
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5 DISCUSSION 
 
5.1 SEROTONIN 
 
Serotonin was present in platelets of the involved skin. This is a well-known 
localization for serotonin. However, we did not detect any serotonin expression in the 
platelets of non-involved and normal skin. This could most probably be explained by 
the fact that in a high grade of inflammation, an enhanced vascularization, as in the 
involved skin will occur compared to in the non-involved and normal skin. There are 
findings supporting that altered platelet levels of serotonin may be involved in elevated 
blood pressure levels and cardiovascular disease.
108
 Psoriasis is also associated with an 
increased risk of cardiovascular disease
104,109-111
. It might be that serotonergic pathways 
can contribute to this comorbidity in psoriasis. 
   The focal serotonin expression in keratinocytes evident in two patients in the involved 
skin in Study II is interesting, even though no definitive conclusions can be drawn from 
such small findings. This is in contrast to earlier studies by Huang et al.
38
 in which 
serotonin expression in psoriasis was observed in prickle cells, sweat gland cells, 
sebaceous gland cells and hair roots with a more prominent staining in ‘progressive’ 
psoriasis compared to the ‘static’ stage of disease. These differences in serotonin 
expression might be explained by different patient characteristics and different 
technical procedures. We used immunohistochemistry on biopsies treated with Lanas 
fix with polyclonal antibody to serotonin, while Huang and colleagues used paraffin-
embedded tissue and a “Rabbit anti-serotonin multicolonal antibody”.  
   Whether the focal staining seen in the keratinocytes was cytoplasmatic or membrane 
attached was not assessable.  
 
5.2 SEROTONIN RECEPTORS 
 
The expression of 5-HT1AR was mainly localized to mast cells and melanocytes. The 
mast cells produce important inflammatory cytokines and neuropeptides
112
 and the 
number of mast cells are increased in psoriasis.
113
 A 5-HT1A-mediated promotion of 
cell survival and proliferation of mitogen-activated T and B lymphocytes,
45
 a 5-HT1AR 
stimulation that inhibits apoptosis in neuronal cells,
114,115
 and a protection of NK cells 
against oxidation-induced apoptosis
116
 may contribute to a prolonged life span of mast 
cells in psoriasis, leading to prolonged release of proinflammatory cytokines and 
neuropeptides, thus maintaining chronic inflammation. Moreover, the flare-up of 
psoriasis during stress conditions might be explained by hormonal effects through 5-
HT1AR on mast cells and the subsequent release of inflammatory mediators.  
   In the brain, the firing rate of serotonergic neurons is inhibited by 5-HT1AR and 
results in a decreased release of serotonin from these cells. Melanocytes may contain 
serotonin. 
40,41,117
 We do not know if a similar mechanism occurs in melanocytes, 
constituting an autocrine system, where released serotonin would feedback on the cell 
through the 5-HT1AR. 
   The increased immunoreactivity in the upper epidermis in involved skin might be 
explained by the fact that the normal keratinocyte differentiation process is changed 
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and the presence of 5-HT1AR may suggest an up-regulation of the receptor due to 
decreased activation.
30
 It has been reported that 5-HT1AR is important in preventing 
apoptosis in neuronal cells and hippocampal HN2-5 cells.
47
 A decreased activation of 
5-HT1AR may lead to stimulated apoptosis and it could be that the keratinocytes in 
upper epidermis enter apoptosis, leading to an increased turnover of keratinocytes. 
   The most important finding is the decreased expression of 5-HT1AR-positive cells in 
the papillary dermis. These cells were mainly mast cells and some lymphocytes. 5-
HT1AR might influence inflammation in psoriasis by mechanisms described above or 
by another pathway, with altered neuropeptide release supporting TNFα-induced 
inflammation. Furthermore, a 5-HT1AR agonist (buspirone) could suppress a contact-
allergy reaction.
54
 
 
There was an increase of 5-HT2AR-positive cells in papillary dermis and double-
staining indicated that they were lymphocytes. DOI, a 5-HT2AR agonist, was able to 
potently inhibit the effects of TNFα.61 In another disease with chronic and TNFα-driven 
inflammation, RA, it was observed that the density of 5-HT2AR was decreased, 
suggesting a possible role for reduced expression of the 5-HT2AR in the sensitization 
of cells to TNFα in RA.118 An up-regulation of 5-HT2AR could reflect a high 
inflammation or being a stimulator of inflammation. This effect of 5-HT2AR in 
involved skin was also seen in the delayed type hypersensitive reaction, where a 5-
HT2AR antagonist (ketanserin) could suppress a contact-allergy reaction.
57
  
   The different dynamics of reversed expression in involved skin, with a decrease of 5-
HT1AR and increase of 5-HT2AR expression are intriguing since in short 5-HT1AR 
suppresses inflammation and 5-HT2AR triggers inflammation. These two receptors 
may work together in an antagonistic way to maintain inflammation in psoriasis. 
 
The reduced immunoreactivity of 5-HT3R in involved skin in basal epidermis 
implicates that it may affect keratinocyte proliferation and differentiation. 5-HT3R 
antagonists inhibit the stimulated release of SP, neurokinin A and CGRP from primary 
afferents
119
 and prevent unmasking of autonomous tachykinin NK2R.
120
 Diminished 5-
HT3R may therefore affect neuropeptides in psoriasis. 
 
Regarding the role of the serotonergic mechanisms in psoriasis our findings are just 
hypothesis-generating. To further elucidate the role of the serotonergic receptors in 
psoriasis it would be interesting to examine their contact with the nerve endings. We 
know that serotonergic receptors were expressed in immune cells and mast cells in the 
papillary dermis where they are in close contact with nerve endings. Double staining 
with a marker for nerve endings could be useful.  
   Another key issue is the functionality of the receptors. Are we staining functionally 
active receptors? It would be very useful to perform a ligand-binding study where 
either skin biopsies or a cell line (for example keratinocytes) would be treated with a 
specific agonist or antagonist and then the activity of the involved receptors could be 
measured. So far this technique is not available in skin specimens. 
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5.3 SERT 
 
The expression of SERT-positive cells in the epidermis and papillary dermis of the 
involved skin is increased in involved skin as compared to normal skin and the non-
involved skin. These findings are in agreement with earlier findings in other 
inflammatory dermatoses such as atopic eczema
121
 and allergic contact eczema.
36
 We 
also determined that increased epidermal SERT expression in inflammatory cells is 
correlated to psoriasis severity and chronic stress, implicating a role for the serotonergic 
system in psoriasis. 
 
Double staining revealed that SERT-positive cells in the epidermis were either 
dendritic cells or lymphocytes and in the papillary dermis lymphocytes or mast cells. 
One disadvantage with the double staining procedure in Study II was that we did not 
count the percentage of SERT-positive cells that expressed CD1a, CD3, or tryptase. 
However, we did that for caspase-3 in Study II and for CD1a and LAMP in Study III. 
We can conclude that the majority of SERT-positive cells in epidermis are dendritic 
cells and that the SERT-positive cells in the papillary dermis were mainly mast cells or 
lymphocytes. 
   Dendritic cells have a key role in the pathogenesis of psoriasis, bridging the gap 
between innate and adaptive immunity.
8
 Dendritic cells have been reported to express 
functional SERT at a level that is regulated by their state of maturation. Immature 
dendritic cells may sequester serotonin released by platelets or mast cells at sites of 
injury and inflammation and mature dendritic cells may shuttle serotonin between 
activated and naive T cells, thereby amplifying adaptive immune responses.
122
 
Serotonin activates different dendritic cell signaling pathways in a maturation-
dependent manner
123
 and in this respect is able to modulate the release of different 
chemokines and cytokines in human monocytes.
124
 Serotonin could also inhibit 
apoptosis in human monocytes, allowing these cells to remain in the tissue and to 
contribute to chronic inflammation.
125
 In addition, SSRI suppress the ability of 
dendritic cells to present bacterial antigens to T cells and could thus down-regulate the 
resulting T-cell proliferation in a SERT/5-HT-independent manner.
126
 Furthermore, 
migration of dendritic cells may be affected. These modes of actions of SERT might be 
possible explanations for the positive correlation between psoriasis severity and SERT 
expression in Study III. 
 
The co-localization of immunostaining of SERT-positive cells in the papillary dermis 
and caspase-3 might indicate that the immune cells of the skin that enter into apoptosis 
may express SERT. It has been demonstrated that SERT synthesis may be stimulated 
by IFNα, an important cytokine for psoriasis pathogenesis.73 This could lead to a 
regulatory loop in which chronic inflammation and release of IFNα could stimulate 
SERT synthesis that would lead to apoptosis of immune cells, thus maintaining chronic 
inflammation. Modulating the levels of SERT expressed by the immune cells could 
possibly lead to a change in chronic inflammation. This finding led us to Study IV and 
to analyse the use of SSRI in psoriasis. 
 
We also determined a modified epithelial SERT expression, with a stronger basal 
expression in the involved skin as compared to non-involved skin, but also as compared 
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to a weaker apical staining in normal skin. These findings are just observations in ten 
patients with no possibility of further statistical analysis. In another disease with 
chronic inflammation, IBS, there have been numerous reports of modified epithelial 
SERT expression. Levels of SERT mRNA have so far been reported to be elevated in 
the small intestines of patients with IBS,
68
 reduced in rectal biopsies from patients with 
ulcerative colitis and IBS,
69
 and in guinea pig colitis,
70
 and normal in rectal and 
sigmoidal mucosal biopsies from patients with IBS.
71
 This modified epithelial 
expression indicates that SERT may also have a direct role in epithelial proliferation 
and differentiation in psoriasis. 
 
As for the serotonin receptors we lack information about the functionality of the SERT 
expression. At the SERT gene level there were no significant differences in genotype 
distribution and allele frequencies in a German population.
65
 More limitations are the 
lack of patient characteristics in Studies I and II. We had no information of important 
potential confounders such as smoking and alcohol. The patients were not receiving 
systemic or local treatments for the previous two weeks prior to biopsy, but no 
information regarding possible previous systemic or local psoriasis treatments or other 
important medications were obtained. In Studies I and II no information about psoriasis 
severity, chronic stress, gut inflammation or depression was obtained. The present 
results are limited but they generate further questions and new important theories about 
the role for the serotonergic system in psoriasis. 
 
 
5.4 USE OF SSRI IN PSORIASIS 
 
Bearing in mind the possibilities to modify SERT expression our aim was to investigate 
the role of SSRI in psoriasis. The golden standard for such an investigation would be a 
randomized clinical trial. With limited resources that was not an option. Instead we 
conducted a broad population-based cohort study from Swedish healthcare registers 
with incident SSRI treatment as exposure and change in psoriasis treatments (a 
surrogate for psoriasis severity) as outcome. 
 
We demonstrated that patients with mild psoriasis have a decreased need for systemic 
psoriasis treatment after starting SSRI treatment. We also determined that patients with 
severe psoriasis are more likely to have a decreased need for systemic psoriasis 
treatment after SSRI use. 
   One possible explanation would be that treatment of clinical depression will have a 
direct effect on psoriasis symptoms and thus reduce the need for psoriasis treatment or 
an indirect effect where improvement in the exposed subjects’ mood disorder will 
increase their ability to comply with non-systemic psoriasis treatments. Another 
explanation could be a direct biological anti-inflammatory effect of SSRI, either 
involving serotonin signaling pathways or being independent of the serotonergic 
system. Animal studies and some human models have indicated that some SSRI may 
have anti-inflammatory effects.
84,85
 
 
Particular strengths of Study IV include its thorough design with a well-defined study 
base, which minimizes bias while maximizing generalizability of the results. We 
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included two strict criteria for exposure to SSRI. First, to assure incident SSRI 
treatment only patients with a wash-out period of SSRI of one year or longer were 
included. Second, only patients with at least two dispensed prescriptions of SSRI 
during six months were included. This reflects a clinically relevant SSRI treatment, 
since the biological effects of SSRI will take approximately 4-6 weeks to evaluate. 
Patients who face side-effects after a few weeks were not included in this study, since 
available register information prevented us from finding out whether these patients 
stopped treatment because of side-effects or for any other reason. Further strengths are 
that the diagnosis of plaque psoriasis was made by dermatologists, minimizing 
misclassification of disease. Both databases used have high internal validity with 
identity data missing for <0.3% of all items in the Swedish Prescribed Drug Register
94
 
and 0.5% for the National Patient Register. One limitation is that no validation was 
conducted regarding the diagnosis of psoriasis vulgaris. However, it is a clinical 
diagnosis and the ICD-coding system for psoriasis vulgaris is stringent. In RA, another 
disease with chronic inflammation, one validation study from the NPR reported that the 
positive predictive value for RA-diagnosis was around 87-94%.
92
 
   The reference group is strictly matched to allow us to look at the effect of SSRI 
exposure. However, this does not allow us to draw any other conclusions than those we 
studied. One important matching factor is the seasonal variation, not only reflecting the 
clinical impression from Sweden that psoriasis improves during summertime. It is also 
evident that there is a seasonal variation in the binding potential for the target protein of 
SSRI, the SERT.
127
 
 
There are some important limitations to consider. By using systemic psoriasis treatment 
as a construct to measure severe psoriasis it is possible that there is misclassification 
with regard to psoriasis severity. Patients with severe psoriasis may not receive 
systemic treatment and may therefore be misclassified into the mild psoriasis cohort. 
The possibility of misclassification is unlikely to differ between study groups and 
may be regarded as non-differential. Another limitation is that our study design does 
not include those who experience side-effects of SSRI and stop the SSRI treatment 
after one or two months. These individuals could be highly interesting if they develop a 
flare-up of psoriasis as a side-effect. In that case we would overestimate the protective 
effect of SSRI in psoriasis. However, this also strengthens our study since we could be 
certain that the subjects in the two study groups tolerated SSRI and are those who could 
benefit from the possible treatment effects.  
   More limitations to consider include the dermatologist’s delay in changing psoriasis 
treatments even though the patient experiences a change in psoriasis severity. 
Phototherapy is traditionally a fairly common systemic treatment used for psoriasis in 
Sweden. We did not include this entity as a marker for severe psoriasis since it is not 
registered in the Prescribed Drug Register. Phototherapy is recorded in the National 
Patient Register, but there may be variations between counties in the reporting of such 
outpatient treatment procedures. We therefore investigated use of phototherapy and the 
geographical distribution of the patients and we determined no major differences 
between the exposed and the reference groups. We did lack information regarding two 
important confounders, smoking and alcohol. 
 
In conclusion, our results suggest that SSRI may have a protective effect in psoriasis. 
To our knowledge this finding has not been previously described.  
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5.5 METHODOLOGICAL CONSIDERATIONS 
 
Immunohistochemistry is useful in describing expression of receptors and proteins. The 
method is reproducible and transparent in trained hands. One has to be cautious when 
interpreting results from the method for several reasons. First of all the sections 
analyzed are relatively limited parts of a punch biopsy. Furthermore, the 
representativeness of a punch biopsy may differ depending on which area you biopsy. 
We therefore tried to be consequent taking the biopsies from the lower back from both 
involved and non-involved skin and from the reference persons with normal skin. 
Nevertheless the ‘lower back’ is a quite broad area and there may be local differences 
in the skin.  
   All the staining procedures were conducted consecutively for all the patients, 
eliminating staining failures. Six sections from one patient were stained on the same 
glass slide, grouped two-by-two, allowing three possible primary antibodies to be 
employed in the same staining procedure. We chose to have one group of two sections 
with the primary antibodies omitted as control, and the other two groups with the 
primary antibody, a total of four sections per patient. In the case of double staining two 
sections were controls with primary antibody omitted. Two sections were only stained 
with the first antibody and the last two sections were double-stained.  
   Interpreting immunohistochemistry is dependent on the examiner. In all three studies 
the positive cells were always counted by the same observer blinded to the nature of the 
specimen (involved skin, non-involved skin, and normal skin), and the patient 
examined. However, in some cases the acanthosis and broadened rete ridges with thin 
suprapapillary areas were obvious, indicating involved skin. In two of the studies (II 
and III), an independent examiner re-counted the cells and no major differences were 
determined. 
 
Immunohistochemstry only allowed us to describe receptor and protein expression. 
You cannot say if you have stained an active or inactive receptor or protein and 
therefore no statements about functionality can be made.  It would be important to 
follow-up the observed findings and try to use other methods for functionality 
(activation or blocking with receptor agonists or antagonists in a ligand-binding study, 
either in vitro with for example cultured keratinocytes, monocytes or lymphocytes or in 
vivo with skin specimens). We did try to see one form of functionality by correlating 
the expression of SERT with important patient characteristics.  
 
A particular strength is that we have had an internal control in the case of the non-
involved skin. Conversely, psoriasis is a systemic disease and we do not know if there 
are more important observations or inflammatory processes in the non-involved skin 
compared to the involved skin. For example, the numbers of mast cells are increased in 
the non-involved skin in psoriasis,
128
 indicating that there is also inflammation in the 
non-involved skin as well. 
 
As mentioned in the Discussion we lack important information about patient 
characteristics in Studies I and II, which could influence the results.  
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In Study III we used salivary cortisol ratios as an indicator for chronic stress. The use of 
salivary cortisol as a measure of stress is debatable.
10
 In our study we used both a 
dexamethasone-suppressed salivary cortisol level and a mean morning cortisol level of 
three observations. The ratio of the mean of the three values to the last cortisol value 
was determined, a low ratio being an indicator of chronic stress. This method for 
chronic stress has previously been used in other studies.
98,121
 
 
In Study III we used the Beck’s Depression Inventory for measure of depression. A 
more commonly used measurement is Montgomery Åsberg Depression Rating Scale 
(MADRS).  
 
In Study IV we used a population-based cohort study. In a cohort study a number of 
patients with a specific exposure are followed over time and the occurrence of different 
outcomes are studied and compared with an unexposed cohort. A cohort study is 
efficient for unusual exposures but usually not for rare outcomes and gives possibilities 
to study multiple endpoints. Cumulative risks, incidence rates, relative risks and 
attributable risks can be calculated. On the negative side is that cohort studies can be 
costly, time consuming, the validity of the results can be influenced by loss to follow-
up, and there is a risk of selection and information bias. 
129
 This was not the case in our 
study where register data allowed us complete follow-up and already finished study-
time.  
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6 CONCLUSION 
 
 In psoriatic skin the expression of serotonin is limited to platelets in the 
involved skin. 
 
 There is a decreased expression of 5-HT1AR in involved skin as compared to 
normal skin and there is an increased expression of 5-HT2AR in involved skin 
as compared to non-involved and normal skin. This reversed receptor 
expression concords with their antagonist function; 5-HT1AR inhibiting 
inflammation and 5-HT2AR being pro-inflammatory. 
 
 The expression of SERT is increased in involved skin as compared to non-
involved and normal skin. 
 
 An increased SERT expression in inflammatory cells in epidermis correlates to 
psoriasis severity and chronic stress. 
 
 SSRI may have a protective effect in psoriasis, since patients with mild 
psoriasis have a decreased need for systemic psoriasis treatment and patients 
with severe psoriasis are more likely to have a decreased need for systemic 
psoriasis treatment after starting SSRI treatment. 
 
 These findings indicate a role for the serotonergic system in psoriasis both as a 
neuroimmunological bridge between the psychological symptoms and the 
disease, as well as an actor in the inflammatory process. 
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7 QUESTIONS FOR THE FUTURE 
 
 Is the change in serotonin receptors and SERT expression observed by 
immunohistochemistry related to functional differences?  
 
 Is there a therapeutic potential of selective modulation of 5-HT1A and 5-HT2A 
receptors for the treatment of psoriasis? 
 
 Are SSRI a possible new and easily accessible treatment option for psoriasis? 
Future clinical trials would be of interest. 
 
 Are there other treatments strategies to modulate SERT in the skin, such as for 
example topical treatments, not having the systemic effects of SSRI? 
 
 Could it be that the important serotonergic mechanisms in psoriasis are due to 
the presence of SERT and serotonin receptors in keratinocytes?  
 
 Is there a correlation between a functional SERT gene polymorphism and the 
severity of disease? 
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8 SUMMARY IN SWEDISH 
 
Psoriasis är en kronisk inflammatorisk hudsjukdom, 2-3% av alla svenskar är drabbade. 
Stress försämrar psoriasis. En viktig signalsubstans vid stressutlöst inflammation är 
serotonin. Serotonin utöver sina effekter via ett antal olika serotoninreceptorer, varav 
två stycken är bättre karaktäriserade än andra – serotonin receptor 1A och serotonin 
receptor 2A. Serotonins inflammatoriska effekt regleras av ett transportörprotein, 
serotonin transporter protein (SERT). Vid inflammatoriska sjukdomar såsom psoriasis 
och IBS (Irritable Bowel Syndrome) är nivåerna av detta protein ändrat och det tycks 
spegla den inflammatoriska aktiviteten.  
 
Vårt mål var att kartlägga vad som driver den inflammatoriska processen vid psoriasis 
och om det serotonerga systemet kan vara involverat. En ökad förståelse av vad som 
driver den inflammatoriska processen vid psoriasis kan på sikt leda till nya 
behandlingsmetoder av sjukdomen. 
 
I de första tre studierna använde vi oss av involverad och icke-involverad hud från 
psoriasispatienter och från friska individer. Huden fryssnittades och därefter användes 
en färgningsteknik, där antikroppar som binder till serotonin receptorer eller SERT syns 
i mikroskopet. På så sätt kan man jämföra förekomsten av dessa receptorer och SERT 
mellan friska individer och psoriasispatienters involverade och icke-involverade hud. 
 
 I den första studien sågs minskad förekomst av serotonin receptor 1A i den involverade 
huden och en ökad förekomst av serotonin receptor 2A jämfört med den icke-
involverade och den friska huden. I den andra studien sågs ökad förekomst av SERT i 
inflammatoriska celler i den involverade huden jämfört med den icke-involverade och 
den friska huden. I den tredje studien kunde vi påvisa att ju större förekomst av SERT i 
överhuden desto större var svårighetsgraden av psoriasis. Dessutom kunde vi påvisa att 
ju större förekomst av SERT i överhuden desto högre grad av kronisk stress uppvisade 
patienterna.  
 
Genom att påverka nivåerna av SERT skulle man kanske kunna påverka 
inflammationsprocessen i psoriasis. Ett sådant preparat är 
serotoninåterupptagshämmarna (SSRI – ”lyckopiller” vid depression). Detta ledde fram 
till den fjärde studien, där vi genom de unika svenska hälsoregistren kunde få fram 
69835 individer med psoriasis, där 1282 individer hade behandlats med SSRI under 
åtminstone 6 månader och 1282 individer med samma kön, ålder, boenderegion, 
svårighetsgrad av psoriasis, och given SSRI behandling under samma tidsperiod på 
året. När man jämförde dessa två grupper visade det sig att de som fått SSRI i mindre 
utsträckning behövde ”tyngre” psoriasisbehandling. Således visade studien att det tycks 
finnas en skyddande effekt av SSRI behandling vid psoriasis. 
 
Med den här avhandlingen konstateras att det serotonerga systemet tycks ha en 
inverkan på den inflammatoriska processen vid psoriasis. 
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